News|Articles|November 16, 2026

FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia

Listen
0:00 / 0:00

Key Takeaways

  • Obinutuzumab is now FDA-approved for pMN to induce proteinuria remission, delivering 36.1% complete remission at 104 weeks versus 5.7% with tacrolimus in Phase III Majesty.
  • B-cell targeting in pMN translated into superior overall remission at week 104 (50% vs 12.9%) without new safety signals, extending obinutuzumab’s footprint in immune-mediated kidney diseases.
SHOW MORE

FDA approves Genentech’s Gazyva, Alexion’s Klygefa, and Teva’s Igalm.

A trio of new FDA approvals is reshaping treatment options across three very different patient populations this week, as each deliver a first-of-its-kind therapy to patients who previously had no approved option built specifically for their condition.

Genentech wins first FDA approval for Gazyva

FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria.

The approval marks Gazyva as the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation. pMN is a chronic autoimmune disease that can lead to kidney failure and carries a substantial human and economic burden for patients, caregivers and health systems alike; proteinuria is a key indicator of kidney damage characterized by high urine protein levels.1

The approval is based on positive results from the Phase III Majesty study, which met its primary endpoint with 36.1% of adults achieving a complete remission of proteinuria at two years (104 weeks) with Gazyva versus 5.7% with tacrolimus.1 Key secondary endpoints show that Gazyva was superior to tacrolimus in achieving overall remission at week 104 (50% vs. 12.9%) and complete remission at week 76 (36.1% vs. 8.6%).1 Safety was in line with Gazyva’s well-characterized profile, and no new safety signals were identified.

“The FDA approval of Gazyva represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” says Levi Garraway, M.D., Ph.D., chief medical officer and head of global product development, Genentech. “With Gazyva, we are turning decades of specialized antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases.”

The recent approval marks the third by FDA of Gazyva in immune-mediated kidney diseases, following approvals in idiopathic nephrotic syndrome and lupus nephritis.1 FDA is currently evaluating Gazyva for adults with systemic lupus erythematosus and is expected to make a decision by December 2026.

Alexion receives approval for Klygefa

Klygefa (gefurulimab) has been approved in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.2

The approval was based on positive results from the pivotal Prevail Phase III trial, in which Klygefa met its primary endpoint, demonstrating improvement from baseline in Myasthenia Gravis Activities of Daily Living total score at week 26 compared to placebo (treatment difference: -1.6; 95% confidence interval: -2.4, -0.8; p<0.0001), with clinical improvement observed as early as week one.2 Klygefa was generally well-tolerated, with a safety profile consistent with previous trials of the C5 inhibitors eculizumab and ravulizumab in gMG.2

Kelly Gwathmey, MD, associate professor in the Department of Neurology’s Division of Neuromuscular Medicine at Columbia University Vagelos College of Physicians and Surgeons and principal investigator in the trial at Virginia Commonwealth University, says: “gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals. In the Prevail Phase III trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection.”

Samantha Masterson, president and chief executive officer, Myasthenia Gravis Foundation of America, says: “For the gMG community, every new approved treatment represents more than a clinical advance; it also represents choice.” Marc Dunoyer, chief executive officer, Alexion, adds that: “The US approval of Klygefa delivers a first-of-its-kind treatment for gMG that offers the efficacy of C5 inhibition with the flexibility of once-weekly subcutaneous self-administration via autoinjector.”

Klygefa is approved in the European Union, Japan and other countries for certain adults with gMG, and regulatory submissions based on the Prevail results are under review in China and additional countries.2

FDA approves at-home use of Igalmi

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced FDA approval of Igalmi (dexmedetomidine) sublingual film for at-home use.3 With this approval, Igalmi becomes the first FDA-approved treatment that can be used at home for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. Agitation associated with these conditions affects between 25% and 40% of patients across them, and acute agitation can escalate quickly; in up to 21% of cases, it can result in an emergency department visit or hospitalization.3

In the Phase III Serenity At-Home Safety and Tolerability Trial, 1,160 agitation episodes in 102 patients were treated with Igalmi, and tolerability remained consistent with repeat dosing over the 12-week study period.3 The most commonly reported adverse events, occurring in 5% or more of patients and at a higher rate than placebo, were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypesthesia, with no discontinuations due to tolerability in the trial.

“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” says Chris Fox, executive vice president, U.S. commercial and head of innovative franchise at Teva. Eric Hughes, M.D., Ph.D., executive vice president, global R&D and chief medical officer at Teva, added: “Innovation in neuroscience is about discovering new medicines and also about rethinking when, where and how treatment can be delivered. The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”

Sources

  1. Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy Genentech November 16, 2026, https://www.businesswire.com/news/home/20261115934247/en/Genentechs-Gazyva-Becomes-the-First-FDA-Approved-Treatment-for-Primary-Membranous-Nephropathy
  2. Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients AstraZeneca November 16, 2026, https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html
  3. U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults Teva Pharmaceuticals https://www.tevapharm.com/news-and-media/latest-news/u.s.-fda-approves-igalmi-as-first-at-home-acute-treatment-for-agitation-associated-with-schizophrenia-s

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.